Ultragenyx Pharmaceutical(GB:0LIF)
$16.55-0.80 (-4.61%)
GB:0LIF
Ultragenyx Pharmaceutical financials statements
$16.55
At close:-0.80 (-4.61%)
Ultragenyx Pharmaceutical (0LIF) Income Statement
0 Followers
Ultragenyx Pharmaceutical Income Statement
Last quarter (Q3 2026), Ultragenyx Pharmaceutical's total revenue was $173.00M, an increase of 8.17% from the same quarter last year. In Q3, Ultragenyx Pharmaceutical's net income was $-118.00M. See Ultragenyx Pharmaceutical’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 673.00M | $ 560.23M | $ 434.25M | $ 363.33M | $ 351.41M | |
| $ 564.00M | $ 483.50M | $ 389.04M | $ 335.01M | $ 335.40M | |
| $ 1.10B | $ 1.02B | $ 958.25M | $ 983.93M | $ 717.13M | |
| Depreciation and Amortization | $ 35.00M | $ 35.54M | $ 26.01M | $ 18.22M | $ 13.24M |
| $ -474.00M | $ -469.00M | $ -516.45M | $ -640.49M | $ -410.32M | |
| $ -535.00M | $ -535.97M | $ -569.21M | $ -648.92M | $ -381.74M | |
| $ -36.00M | $ -31.61M | $ -39.26M | $ -52.81M | $ -71.24M | |
| $ -571.00M | $ -567.59M | $ -608.46M | $ -701.73M | $ -452.98M | |
| $ -575.00M | $ -569.18M | $ -606.64M | $ -707.42M | $ -454.02M | |
| Per Share Metrics | |||||
| Basic EPS | $ -5.83 | $ -6.29 | $ -8.25 | $ -10.12 | $ -6.70 |
| Diluted EPS | $ -5.83 | $ -6.29 | $ -8.25 | $ -10.12 | $ -6.70 |
| Weighted Average Shares Outstanding | 98.60M | 90.54M | 73.54M | 69.91M | 67.80M |
| Weighted Average Shares Outstanding (Diluted) | 98.60M | 90.54M | 73.54M | 69.91M | 67.80M |
Currency in USD

